Top

Journal of Neuro-Oncology

Published in:

01-07-2014 | TOPIC REVIEW & CLINICAL GUIDELINES

The role of radiotherapy in the management of progressive glioblastoma

A systematic review and evidence-based clinical practice guideline

Authors: Samuel Ryu, John M. Buatti, Ann Morris, Steven N. Kalkanis, Timothy Charles Ryken, Jeffrey J. Olson

Published in: Journal of Neuro-Oncology | Issue 3/2014

Abstract

Question

Can re-irradiation (by using conventional radiotherapy, fractionated radiosurgery, or single fraction radiosurgery) be used in patients with progressive glioblastoma multiforme after the first adjuvant combined multimodality treatment with radiation and chemotherapy?

Target population

These recommendations apply to adult patients with progressive glioblastoma after first line combined multimodality treatment with chemotherapy and radiation.

Recommendations

Level III

When the target tumor is amenable for additional radiation, re-irradiation is recommended as it provides improved local tumor control, as measured by best imaging response. Such re-irradiation can take the form of conventional fractionation radiotherapy, fractionated radiosurgery, or single fraction radiosurgery.

Level III

Re-irradiation is recommended in order to maintain or improve a patient’s neurological status and quality of life prior to any further tumor progression.

Darefsky AS, King JT Jr, Dubrow R (2012) Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries. Cancer 118(8):2163–2172PubMedCentralPubMedCrossRef

Koshy M, Villano JL, Dolecek TA et al (2012) Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol 107(1):207–212PubMedCrossRef

Easaw JC, Mason WP, Perry J et al (2011) Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Curr Oncol 18(3):e126–e136PubMedCentralPubMedCrossRef

Olson JJ, Fadul CE, Brat DJ, Mukundan S, Ryken TC (2009) Management of newly diagnosed glioblastoma: guidelines development, value and application. J Neurooncol 93(1):1–23PubMedCrossRef

Olson JJ, Ryken T (2008) Guidelines for the treatment of newly diagnosed glioblastoma: introduction. J Neurooncol 89(3):255–258PubMedCrossRef

Prados M, Cloughesy T, Samant M et al (2011) Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 13(1):143–151PubMedCentralPubMedCrossRef

Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733–4740PubMedCrossRef

Dirks P, Bernstein M, Muller PJ, Tucker WS (1993) The value of reoperation for recurrent glioblastoma. Can J Surg 36(3):271–275PubMed

Guyotat J, Signorelli F, Frappaz D, Madarassy G, Ricci AC, Bret P (2000) Is reoperation for recurrence of glioblastoma justified? Oncol Rep 7(4):899–904PubMed

10.

Pannullo SC, Fraser JF, Moliterno J, Cobb W, Stieg PE (2011) Stereotactic radiosurgery: a meta-analysis of current therapeutic applications in neuro-oncologic disease. J Neurooncol 103(1):1–17PubMedCrossRef

11.

Nieder C, Astner ST, Mehta MP, Grosu AL, Molls M (2008) Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma. Am J Clin Oncol 31(3):300–305PubMedCrossRef

12.

Souhami L, Seiferheld W, Brachman D et al (2004) Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 60(3):853–860PubMedCrossRef

13.

Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D (2005) Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 23(34):8863–8869PubMedCrossRef

14.

Patel M, Siddiqui F, Jin JY et al (2009) Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival. J Neurooncol 92(2):185–191PubMedCrossRef

15.

Hudes RS, Corn BW, Werner-Wasik M et al (1999) A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys 43(2):293–298PubMedCrossRef

16.

Minniti G, Armosini V, Salvati M et al (2011) Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma. J Neurooncol 103(3):683–691PubMedCrossRef

17.

Schwer AL, Damek DM, Kavanagh BD et al (2008) A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 70(4):993–1001PubMedCrossRef

18.

Shepherd SF, Laing RW, Cosgrove VP et al (1997) Hypofractionated stereotactic radiotherapy in the management of recurrent glioma. Int J Radiat Oncol Biol Phys 37(2):393–398PubMedCrossRef

19.

Grosu AL, Weber WA, Franz M et al (2005) Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 63(2):511–519PubMedCrossRef

20.

Gutin PH, Iwamoto FM, Beal K et al (2009) Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75(1):156–163PubMedCentralPubMedCrossRef

21.

Maranzano E, Anselmo P, Casale M et al (2011) Treatment of recurrent glioblastoma with stereotactic radiotherapy: long-term results of a mono-institutional trial. Tumori 97(1):56–61PubMed

22.

Elliott RE, Parker EC, Rush SC et al (2011) Efficacy of gamma knife radiosurgery for small-volume recurrent malignant gliomas after initial radical resection. World Neurosurg 76(1–2):128–140; discussion 161–122PubMedCrossRef

23.

Kondziolka D, Flickinger JC, Bissonette DJ, Bozik M, Lunsford LD (1997) Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms. Neurosurgery 41(4):776–783; discussion 783–775PubMedCrossRef

24.

Combs SE, Bischof M, Welzel T et al (2008) Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas. J Neurooncol 89(2):205–210PubMedCrossRef

25.

Lederman G, Wronski M, Arbit E et al (2000) Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am J Clin Oncol 23(2):155–159PubMedCrossRef

26.

Schwer AL, Kavanagh BD, McCammon R et al (2009) Radiographic and histopathologic observations after combined EGFR inhibition and hypofractionated stereotactic radiosurgery in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 73(5):1352–1357PubMedCrossRef

27.

Torcuator R, Thind R, Patel M et al (2010) The role of salvage reirradiation for malignant gliomas that progress on bevacizumab. J Neurooncol 97(3):401–407PubMedCrossRef

28.

Prados M, Cloughesy T, Samant M et al (2011) Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro-Oncology 13(1):143–151PubMedCentralPubMedCrossRef

29.

Park KJ, Kano H, Iyer A et al (2012) Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case-control study. J Neurooncol 107(2):323–333PubMedCrossRef

30.

Cuneo KC, Vredenburgh JJ, Sampson JH et al (2012) Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 82(5):2018–2024PubMedCentralPubMedCrossRef

31.

Nieder C, Nestle U, Ketter R et al (1999) Hyperfractionated and accelerated-hyperfractionated radiotherapy for glioblastoma multiforme. Radiat Oncol Investig 7(1):36–41PubMedCrossRef

32.

Cho KH, Hall WA, Gerbi BJ, Higgins PD, McGuire WA, Clark HB (1999) Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys 45(5):1133–1141PubMedCrossRef

33.

Combs SE, Gutwein S, Thilmann C, Huber P, Debus J, Schulz-Ertner D (2005) Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme. J Neurooncol 74(2):167–171PubMedCrossRef

34.

Fokas E, Wacker U, Gross MW, Henzel M, Encheva E, Engenhart-Cabillic R (2009) Hypofractionated stereotactic reirradiation of recurrent glioblastomas: a beneficial treatment option after high-dose radiotherapy? Strahlenther Onkol 185(4):235–240PubMedCrossRef

35.

Fogh SE, Andrews DW, Glass J et al (2010) Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol 28(18):3048–3053PubMedCentralPubMedCrossRef

36.

Combs SE, Widmer V, Thilmann C, Hof H, Debus J, Schulz-Ertner D (2005) Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM). Cancer 104(10):2168–2173PubMedCrossRef

37.

Shrieve DC, Alexander E, Wen PY et al (1995) Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery 36(2):275–282; discussion 282–274PubMedCrossRef

38.

Hsieh PC, Chandler JP, Bhangoo S et al (2005) Adjuvant gamma knife stereotactic radiosurgery at the time of tumor progression potentially improves survival for patients with glioblastoma multiforme. Neurosurgery 57(4):684–692; discussion 684–692PubMed

39.

Mahajan A, McCutcheon IE, Suki D et al (2005) Case-control study of stereotactic radiosurgery for recurrent glioblastoma multiforme. J Neurosurg 103(2):210–217PubMedCrossRef

40.

Hall WA, Djalilian HR, Sperduto PW et al (1995) Stereotactic radiosurgery for recurrent malignant gliomas. J Clin Oncol 13(7):1642–1648PubMed

41.

Brazil L, Thomas R, Laing R et al (1997) Verbally administered Barthel Index as functional assessment in brain tumour patients. J Neurooncol 34(2):187–192PubMedCrossRef

42.

Ernst-Stecken A, Ganslandt O, Lambrecht U, Sauer R, Grabenbauer G (2007) Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma. J Neurooncol 81(3):287–294PubMedCrossRef

43.

Neider C, Nestle U, Niewald M, Walter K, Schnabel K (1999) Hyperfractionated reirradiation for malignant glioma. Front Radiat Ther Oncol 33:150–157PubMedCrossRef

Title: The role of radiotherapy in the management of progressive glioblastoma
A systematic review and evidence-based clinical practice guideline
Authors: Samuel Ryu
John M. Buatti
Ann Morris
Steven N. Kalkanis
Timothy Charles Ryken
Jeffrey J. Olson
Publication date: 01-07-2014
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2014
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-013-1337-6

At a glance: The STEP trials

Springer Medicine

The role of radiotherapy in the management of progressive glioblastoma

A systematic review and evidence-based clinical practice guideline

Abstract

Question

Target population

Recommendations

Level III

Level III

At a glance: The STEP trials

Springer Medicine

Abstract

Question

Target population

Recommendations

Level III

Level III

Please log in to get access to this content

Other articles of this Issue 3/2014

Glioblastoma at progression: therapy of a challenging problem addressed candidly with evidence-based techniques

Introduction, rationale, and methodology

The role of imaging in the management of progressive glioblastoma

The role of cytotoxic chemotherapy in the management of progressive glioblastoma

The role of neuropathology in the management of progressive glioblastoma

The role of cytoreductive surgery in the management of progressive glioblastoma